Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model
Richard Mutell, Jaime L Rubin, T Christopher Bond, Tracy Mayne DaVita Clinical Research, Minneapolis, MN, USA Background: Ferric citrate (FC) is a phosphate binder in development for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD). In clinical trials, FC improved p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-04-01
|
| Series: | International Journal of Nephrology and Renovascular Disease |
| Online Access: | http://www.dovepress.com/reduced-use-of-erythropoiesis-stimulating-agents-and-intravenous-iron--a12911 |